论文部分内容阅读
本次年会上公布的一项研究显示,在新确诊的1型糖尿病患者中,糖尿病确诊后12个月,免疫疗法可以改善胰岛β细胞的功能。该研究纳入了年龄在8～14岁对抗CD3抗体免疫疗法反应良好的患者,3个月内诊断为1型糖尿病的患者。该项抗CD3单克隆抗体teplizum ab的随机、安慰剂对照试验,共纳入58名患者,平均年龄12.3岁,4～12个月前被诊断为1型糖尿病,C肽水平超过0.2pmol/mL,基线胰岛素剂量为0.40U/kg·d。试验开始之前,所有患者均接受
A study published at the annual meeting showed that immunotherapy improved the function of pancreatic β-cells in newly diagnosed type 1 diabetic patients 12 months after the diagnosis of diabetes. The study enrolled patients aged 8-14 years who responded well to anti-CD3 antibody immunotherapy and who were diagnosed with type 1 diabetes within 3 months. The randomized, placebo-controlled trial of the anti-CD3 monoclonal antibody teplizum ab enrolled 58 patients, mean age 12.3 years, diagnosed with type 1 diabetes 4-12 months ago and C-peptide levels above 0.2 pmol / mL, Baseline insulin dose was 0.40 U / kg · d. All patients received prior to the start of the experiment